In addition, investigation of the cytocompatibility of free TB vs. that of the peptide loaded into CS-NPs, highlighted an excellent role of the nanocarrier in reducing the peptide’s toxicity toward mammalian cells, thus representing a promising model for the development of NPs-based delivery system of AMPs with therapeutic potential. This evidence concerns the gene ADSL and tuberculosis.